Results 181 to 190 of about 130,425 (315)

KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer [PDF]

, 2007
Erminia Massarelli, Marileila Varella‐Garcia, Ximing Tang, Ana C. Xavier, Natalie Ozburn, Diane D. Liu, B. Nebiyou Bekele, Roy S. Herbst, Ignacio I. Wistuba   +8 more
openalex   +1 more source

Electrochemical Three‐Component Synthesis of Vinyl Sulfonamides via Decarboxylative Sulfonylation of Cinnamic Acids

ChemSusChem, EarlyView.
An efficient, metal‐free electrochemical three‐component reaction of cinnamic acids, SO2, and amines to access (E)‐β‐styryl sulfonamides is reported. Utilizing graphite electrodes and SO2 stock solutions, this decarboxylative protocol proceeds under mild conditions with high regio‐ and stereoselectivity.
Po‐Chung Chien, Harald Kelm, Georg Manolikakes   +2 more
wiley   +1 more source

Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. [PDF]

J Transl Med
Liu M, Seier K, Gonen M, Sigel C, Jung J, Blair AB, Howell TC, Reidy-Lagunes D, Lidsky ME, Allen PJ, Blazer Iii DG, Zani S, Wei AC, Drebin JA, Balachandran V, D'Angelica M, Soares KC, Kingham TP, Jarnagin WR.   +18 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Targeted therapy for KRAS G12C-mutated colorectal cancer: advances, challenges, and future directions. [PDF]

Am J Cancer Res
Lin Y, Cheng SH, Wang D, Zhang SH, Li HL.   +4 more
europepmc   +1 more source

A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of <i>KRAS</i> Mutations. [PDF]

Cancers (Basel)
Motta L, Epistolio S, Pankovics J, Molinari F, Pedrazzini B, Valera A, Giudici L, Freguia S, Patella M, Imbimbo M, Schiavone G, Frattini M, Froesch P.   +12 more
europepmc   +1 more source

GTPase KRas [PDF]

, 2020
openaire   +1 more source

ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer

, 2009
Roscoe F. Morton, Elizabeth H. Hammond
openalex   +1 more source

Loss of the Y Chromosome in Oral Potentially Premalignant Disorders Predicts Malignant Progression: An Integrative Cross‐Species Multi‐Cohort Bioinformatic Study

Head &Neck, EarlyView.
ABSTRACT Background The loss of the Y chromosome (LOY) and the extreme down‐regulation of Y chromosome gene expression (EDY) are frequently observed in oral squamous cell carcinoma (OSCC). However, their roles in oral potentially malignant disorders (OPMDs) are unclear.
Rui Han, Jos B. Poell, Cristina Conde‐Lopez, Tuula Salo, Ina Kurth, Ruud H. Brakenhoff, Jochen Hess   +6 more
wiley   +1 more source

KRAS-Driven Hypertranscription and Metastatic Dissemination in Colorectal Cancer Could be Overcome by Targeting the NMHC IIA/ PLK1 Signaling Axis with a Novel Acridine Derivative. [PDF]

Int J Biol Sci
Ji D, Yi H, Li M, Gao Z, Yang R, Jia J, Cui X, Song C, Wang H, Shi M, Yan Y, Geng T, Meng X, Li Z, Gu J.   +14 more
europepmc   +1 more source